Abeona Therapeutics recently secured a permanent J-code for its ZEVASKYN treatment, facilitating reimbursement in the U.S. This marks a positive step for future commercialization and revenue growth. Additionally, the company strengthened its leadership team by appointing James A. Gow as Senior Vice President of Clinical Development and Medical Affairs, reflecting its commitment to accelerating therapy development. Abeona also granted restricted stock to eleven new employees in compliance with Nasdaq rules to support its expansion. These combined developments reinforce confidence in the company’s growth strategy within the biopharmaceutical gene and cell therapy market.